Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study

Abstract

Tegaserod is a first-in class selective serotonin 4 receptor agonist approved for the treatment of irritable bowel syndrome. In March 2007, the US Food and Drug Administration (FDA) suspended its use citing increased cardiovascular (CV) events in clinical trials. However, there is no known mechanistic basis for an adverse CV effect. To reassess the CV safety of tegaserod, teagaserod-treated patients (pts) in the Intermountain Healthcare database were identified (n = 2603), matched 1:6 with untreated (n = 15,618) patients by age, sex, and date of tegaserod initiation, and followed for an average of 2.5 years. Age averaged 38.6 ± 13.5 years, and 94% were female. Cardiovascular event rates were low and similar in patients treated with tegaserod and matched untreated patients. For the primary composite CV endpoint, 54 (0.35%) untreated and 12 (0.46%) treated pts had an event (treated OR = 1.27, 95% CI: 0.68-2.38, P =.46), with 7 and 0 events, respectively, occurring within 3 months. A total of 12 (0.1%) untreated and 1 (<0.1%) treated pts were hospitalized for a myocardial infarction (MI). 36 (0.2%) untreated and 10 (0.4%) treated pts for a cardiovascular accident, and 1 pt in each group for unstable angina. A total of 6 (<0.1%) untreated and no treated pts died from cardiac causes. Event rates were comparable to expected rates in this population of mostly premenopausal women. This large epidemiologic study failed to confirm a reported large event differential for tegaserod that was noted incidentally in a clinical trials database, suggesting that the prior observation may have been due to chance.

Keywords

tegaserod adverse events cardiovascular epidemiology irritable bowel syndrome safety

References

Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001;120:652-668.

Pudloski S. , Frable A. Novartis suspends US marketing and sales of Zelnorm in response to request from FDA. 2007. http://www.novartis.com/newsroom/media-release/en/2007/index-page3.shtml. Accessed September 21, 2008.

Camilleri M. , Choi MG Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11(1):3-15.

Murray L , ed. Physician’s Desk Reference . Montvale, NJ: Thomson PDR; 2007:2312-2315.

Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther. 2001;15(3):277-289.

Questions and answers on Zelnorm (tegaserod maleate). 2007. www.fda.gov/CDER/Drug/infopage/zelnorm/zelnormQA2007.htm. Accessed April 25, 2009.

Ridker PM , Cook NR , Lee I-M. , et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.

American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.

Kaumann AJ , Levy FO 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006;111(3):674-706.

10.

Prather CM , Camilleri M. , Zinsmeister AR , et al. Tegaserod accelerates orocecal transit in patients with constipation-redominant irritable bowel syndrome. Gastroenterology. 2000;118(3):463-468.

11.

Bran S. , Murray WA , Hirsch IB , et al. Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995; 155(7):765-768.

12.

Drolet B. , Khalifa M. , Caleau P. , et al. Block of the rapid component of the delayed rectifer potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998; 97(2):204-210.

13.

Morganroth J. , Ruegg PC , Dunger-Baldauf C. , Appel-Dingemanse S. , Bliesath H. , Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol. 2002;97(9):2321-2327.

14.

Mueller-Lissner S. , Fumagalli I. , Bardhan KD , et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation. Aliment. Pharmacol Ther. 2001;15(10): 1655-1666.

15.

Jones BW , Moore DJ , Robinson SM , Song F. A systematic review of tegaserod for the treatment of irritable bowel syndrome . J Clin Pharm Ther. 2003;27(5):343- 352.

16.

Evans BW , Clark WK , Moore DJ , Whorwell PJ Tegaserod for treatment of irritable bowel syndrome. Cochrane Data Base Sys Rev. 2007;17(4):CD003960.

17.

Johanson JF , Wald A. , Tougas G. , et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004; 2(9):796-805.

18.

Kamm MA , Mueller-Lissner S. , Talley NJ , et al. Tegaserod for treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol. 2005;100(2):362-372.

19.

Tougas G. , Snape WJ Jr , Otten MH , et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(10):1701-1708.

20.

Hasler WL , Schoenfeld P. Safety profile of tegaserod, a 5-HT4 receptor agonis, for treatment of irritable bowel syndrome. Drug Saf. 2004;27(9):619-631.

21.

Mainous AG , Koopman RJ , Diaz VA , Everett CJ , Wilson PW , Tilley BC A coronary heart disease risk score based on patient-reported information . Am J Car-diol. 2007;99(9):1236-1241.

22.

Brandt LJ The FDA’s decision-making process: isn’t it time to temper the principle of protective paternalism? Am J Gastroenterol. 2008;103(5):1226-1227.